An efficient biomarker panel for diagnosis of breast cancer using surface-enhanced laser desorption ionization time-of-flight mass spectrometry

Yigitbasi,Turkan; Calibasi-Kocal,Gizem; Buyukuslu,Nihal; Atahan,Murat   Kemal; Kupeli,Hakan; Yigit,Seyran; Tarcan,Ercument; Baskin,Yasemin

doi:10.3892/br.2018.1042

An efficient biomarker panel for diagnosis of breast cancer using surface-enhanced laser desorption ionization time-of-flight mass spectrometry

Authors:
- Turkan Yigitbasi
- Gizem Calibasi-Kocal
- Nihal Buyukuslu
- Murat Kemal Atahan
- Hakan Kupeli
- Seyran Yigit
- Ercument Tarcan
- Yasemin Baskin
View Affiliations

Affiliations: Department of Biochemistry, School of Medicine, Istanbul Medipol University, Istanbul 34810, Turkey, Department of Basic Oncology, Institute of Oncology, Dokuz Eylul University, Izmir 35340, Turkey, Department of Nutrition and Dietetics, School of Health Sciences, Istanbul Medipol University, Istanbul 34810, Turkey, Department of General Surgery, Ataturk Training and Research Hospital, Katip Celebi University, Izmir 35360, Turkey, Department of Pathology, Ataturk Training and Research Hospital, Katip Celebi University, Izmir 35360, Turkey
Published online on: January 15, 2018 https://doi.org/10.3892/br.2018.1042
Pages: 269-274

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer (BC) is the most frequently diagnosed cancer that affects women worldwide. Early detection of BC is important to improve survival rates and decrease mortality. The aim of the present study was to investigate serum biomarkers using surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS) to distinguish patients with BC from the healthy population and patients with benign breast diseases (BBDs). A total of 62 patients with invasive ductal carcinoma, as confirmed by histopathology, and 47 non-cancerous individuals (NCIs) [16 healthy controls (HCs) and 31 patients with BBD] were enrolled in the present study. Serum protein profiles were determined by SELDI‑TOF-MS using an immobilized metal affinity capture array. Serum from patients with BC were compared with that from the HC group using univariate and multivariate statistical analyses. A total of 118 clusters were generated from the individual serum. Univariate analysis revealed that 5 peaks were significantly downregulated (m/z 1,452, 2,670, 3,972, 5,354 and 5,523; P<0.001) and 4 were upregulated (m/z 6,850, 7,926, 8,115 and 8,143; P<0.001) in patients with BC compared with the HC group. A comparison of patients with BC and patients with BBD revealed an additional 9 protein peaks. Among these, 3 peaks (m/z 3,972, 5,336 and 11,185) were significantly downregulated and 6 peaks (m/z 4,062, 4,071, 4,609, 6,850, 8,115 and 8,133) were significantly upregulated. A total of 3 peaks [mass-to-change ratio (m/z) 3,972, 6,850 and 8,115 (BC2)] were common in both sets. The results of the present study suggest that a 4 protein peak set [m/z 3,972, 6,850 and 8,115 (BC2) and 8,949 (BC3)] could be used to distinguish patients with BC from NCI.

View Figures

View References

1	Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, Shi W, Jiang J, Yao PP and Zhu HP: Risk factors and preventions of breast cancer. Int J Biol Sci. 13:1387–1397. 2017. View Article : Google Scholar
2	Rahman M and Mohammed S: Breast cancer metastasis and the lymphatic system. Oncol Lett. 10:1233–1239. 2015. View Article : Google Scholar
3	Niell BL, Freer PE, Weinfurtner RJ, Arleo EK and Drukteinis JS: Screening for breast cancer. Radiol Clin North Am. 55:1145–1162. 2017. View Article : Google Scholar
4	Nothacker M, Duda V, Hahn M, Warm M, Degenhardt F, Madjar H, Weinbrenner S and Albert US: Early detection of breast cancer: Benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue. A systematic review. BMC Cancer. 9:3352009. View Article : Google Scholar
5	Drukteinis JS, Mooney BP, Flowers CI and Gatenby RA: Beyond mammography: New frontiers in breast cancer screening. Am J Med. 126:472–479. 2013. View Article : Google Scholar
6	Baskın Y and Yiğitbaşı T: Clinical proteomics of breast cancer. Curr Genomics. 11:528–536. 2010. View Article : Google Scholar
7	Liu C: The application of SELDI-TOF-MS in clinical diagnosis of cancers. J Biomed Biotechnol. 2011:2458212011. View Article : Google Scholar
8	Li J, Orlandi R, White CN, Rosenzweig J, Zhao J, Seregni E, Morelli D, Yu Y, Meng XY, Zhang Z, et al: Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem. 51:2229–2235. 2005. View Article : Google Scholar
9	Atahan K, Küpeli H, Gür S, Yiğitbaşı T, Baskın Y, Yiğit S, Deniz M, Cökmez A and Tarcan E: The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer. Int J Med Sci. 8:148–155. 2011. View Article : Google Scholar
10	Belluco C, Petricoin EF, Mammano E, Facchiano F, Ross-Rucker S, Nitti D, Di Maggio C, Liu C, Lise M, Liotta LA, et al: Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann Surg Oncol. 14:2470–2476. 2007. View Article : Google Scholar
11	van Winden AW, Gast MC, Beijnen JH, Rutgers EJT, Grobbee DE, Peeters PH and van Gils CH: Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: A case control study. BMC Med Genomics. 2:42009. View Article : Google Scholar
12	Chung L, Moore K, Phillips L, Boyle FM, Marsh DJ and Baxter RC: Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer. Breast Cancer Res. 16:R632014. View Article : Google Scholar
13	Singletary SE and Connolly JL: Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin. 56:37–47. 2006. View Article : Google Scholar
14	Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF and Bast RC Jr; American Society of Clinical Oncology, : American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 25:5287–5312. 2007. View Article : Google Scholar
15	Paweletz CP, Gillespie JW, Ornstein DK, Simone NL, Brown MR, Cole KA, Wang QH, Huang J, Hu N, Yip TT, et al: Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. Drug Dev Res. 49:34–42. 2000. View Article : Google Scholar
16	Nakanishi T, Shimizu A, Okamoto N, Ingendoh A and Kanai M: Analysis of serum protein precipitated with antiserum by matrix-assisted laser desorption ionization/time-of-flight and electrospray ionization mass spectrometry as a clinical laboratory test. J Am Soc Mass Spectrom. 6:854–859. 1995. View Article : Google Scholar
17	Lacey JM, Bergen HR, Magera MJ, Naylor S and O'Brien JF: Rapid determination of transferrin isoforms by immunoaffinity liquid chromatography and electrospray mass spectrometry. Clin Chem. 47:513–518. 2001.
18	Vlahou A, Laronga C, Wilson L, Gregory B, Fournier K, McGaughey D, Perry RR, Wright GL Jr and Semmes OJ: A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer. 4:203–209. 2003. View Article : Google Scholar
19	Yao F, Zhang C, Du W, Liu C and Xu Y: Identification of gene-expression signatures and protein markers for breast cancer grading and staging. PLoS One. 10:e01382132015. View Article : Google Scholar
20	Diamandis EP: Point: Proteomic patterns in biological fluids: Do they represent the future of cancer diagnostics? Clin Chem. 49:1272–1275. 2003. View Article : Google Scholar
21	Higgins SA, Matloff ET, Rimm DL, Dziura J, Haffty BG and King BL: Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer. Breast Cancer Res. 7:R1017–R1022. 2005. View Article : Google Scholar
22	Li J, Zhang Z, Rosenzweig J, Wang YY and Chan DW: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem. 48:1296–1304. 2002.
23	Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, et al The Breast Cancer Linkage Consortium, : Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 62:676–689. 1998. View Article : Google Scholar
24	Vos S, Moelans CB and van Diest PJ: BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers. Breast Cancer Res. 19:642017. View Article : Google Scholar
25	Neagu M, Constantin C, Tanase C and Boda D: Patented biomarker panels in early detection of cancer. Recent Pat Biomark. 1:10–24. 2011. View Article : Google Scholar
26	Mathelin C, Cromer A, Wendling C, Tomasetto C and Rio MC: Serum biomarkers for detection of breast cancers: A prospective study. Breast Cancer Res Treat. 96:83–90. 2006. View Article : Google Scholar
27	Atalay C and Kubilay D: The results of screening with SELDI-TOF-MS method in breast cancer diagnosis. J Breast Health. 7:106–108. 2011.
28	Stearns V, Yamauchi H and Hayes DF: Circulating tumor markers in breast cancer: Accepted utilities and novel prospects. Breast Cancer Res Treat. 52:239–259. 1998. View Article : Google Scholar
29	Gautam A and Verma S, Pantola C and Verma S: Utility of CA 15-3 as diagnostic and prognostic marker in breast cancer. IOSR-JDMS. 14:17–20. 2015.
30	Geng B, Liang MM, Ye XB and Zhao WY: Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. Mol Clin Oncol. 3:232–236. 2015. View Article : Google Scholar
31	Zeidan BA, Cutress RI, Hastie C, Mirnezami AH, Packham G and Townsend PA: SELDI-TOF-MS proteomics in breast cancer. Clin Proteomics. 5:133–147. 2009. View Article : Google Scholar
32	Yin P, Lehmann R and Xu G: Effects of pre-analytical processes on blood samples used in metabolomics studies. Anal Bioanal Chem. 407:4879–4892. 2015. View Article : Google Scholar
33	Chandramouli K and Qian PY: Proteomics: Challenges, techniques and possibilities to overcome biological sample complexity. Hum Genomics Proteomics. 2009:2392042009. View Article : Google Scholar
34	Muthu M, Vimala A, Mendoza OH and Gopal J: Tracing the voyage of SELDI-TOF-MS in cancer biomarker discovery and its current depreciation trend-need for resurrection? Trends Analyt Chem. 76:95–101. 2016. View Article : Google Scholar